ASX Announcement – 21 September 2021

R&D Progress – Molecular Medicine – ASON Project – Results of Dosing Study

Highlights

- Antisense Oligonucleotide RNA Therapeutics Project
- Limited Dosing Study in Humanised-Liver Mouse Model
- Treatment was well-tolerated by the humanised-liver mouse
- Treatment substantially reduced the drug target relative to control
- Treatment suppressed disease markers of liver inflammation and fibrosis
- Treatment increased expression of an anti-fibrotic factor

Results of Limited Dosing Study

Resonance Health Ltd (ASX: RHT) ("Resonance Health" or "Company") provides the following update, further to its announcement on 24 May 2021 ("Filing of International Application under Patent Co-operation Treaty for Method for Treating Viral, Inflammatory and Malignant Disease").

The Antisense Oligonucleotide ("ASO") R&D Project is part of the Company's Molecular Medicine R&D workstream, led by Resonance Health's Dr. Sherif Boulos. The Company recently completed preliminary analysis of its lead compound in a limited dosing study in a humanised-liver mouse model. All three (3) doses of AS3 (5mg/kg, 10mg/kg, and 25mg/kg: subcutaneous administration), induced robust knockdown of the target mRNA# (with an average efficacy of 96%), with the lowest dose achieving 98% efficacy. (*#measured relative to control using a 'gold standard' quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay)*

Project leader, Dr. Sherif Boulos, commented:

"Despite the relatively short six-day duration of the study, we observed inhibition of liver disease related inflammatory and fibrotic disease markers, and a corresponding increase in the expression of an anti-fibrotic factor. Importantly, AS3 was well-tolerated by all the mice, with no evidence of any toxicity. While we caution that our findings are preliminary, they support the continued development of AS3".

In demonstrating that AS3 is highly efficacious in a humanised-liver mouse model, the Company has achieved a significant milestone. On that basis, the Company has commenced discussions with an experienced academic team to develop a collaborative study with the objective of evaluating AS3 in a humanised-liver mouse model of Hepatitis B virus infection. We hope to commence this work late 2021 or early 2022 for completion in the first half of 2022.

The Company looks forward to providing further updates as the ASO R&D Project progresses.

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

For further information please contact:
Mitchell Wells – Managing Director
E: mitchellw@resonancehealth.com
P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company, specialising in the development and delivery of noninvasive medical imaging software and services.

The Company's products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high quality quantitative measurements essential in the management of particular diseases.

Resonance Health's dedication to scientific rigour and quality management has enabled it to achieve regulatory clearances for a range of Software as a Medical Device (**SaMD**) products in the US, Europe, and Australia and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. A number of these SaMD products incorporate the use of Artificial Intelligence (**AI**) in order to improve speed and efficiency of service delivery:

- **FerriScan®** - provides an accurate measurement of liver iron concentration (**LIC**) through a non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. FerriScan is internationally recognised as the gold standard in LIC assessment
- **FerriSmart® -** an AI-driven system for the automated real-time measurement of LIC in patients using non-invasive MRI-based technology
- **HepaFat-AI®** - an AI-driven system for the automated real-time multi-metric measurement of liver fat in patients using non-invasive MRI-based technology, for use in the assessment of individuals with confirmed or suspected fatty liver disease

The Company has an active development pipeline of additional medical imaging analysis products and services, including, **ALERT-PE®**, an AI tool for the automated review of chest CT scans of patients with suspected pulmonary embolism.